Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Review
Overview
abstract
Low-dose oral minoxidil has gained recognition as an off-label treatment for hair loss disorders, including androgenetic alopecia, telogen effluvium, and alopecia areata. Originally developed to treat hypertension, its hair growth-promoting effects are attributed to multiple mechanisms: primarily through direct KATP channel activation in dermal papilla cells, with additional effects from Wnt/β-catenin signaling, enhanced cysteine incorporation, and modulation of inflammatory and androgenic pathways. Clinical studies demonstrate comparable efficacy to topical minoxidil, with the added advantages of improved adherence, lower cost, and reduced application-related side effects. Common adverse effects include dose-dependent hypertrichosis (24% incidence), transient shedding (16-22%), and mild peripheral edema (2%), while serious complications, including pericardial effusion, are rare at doses used for alopecia. International Delphi consensus supports standardized dosing: 1.25 mg/day starting dose for women (range 0.625-5 mg/day) and 2.5 mg/day for men (range 1.25-5 mg/day), with lower doses recommended for adolescents and caution advised in renal/hepatic impairment. Contraindications include pericardial disease, uncontrolled hypertension, and pregnancy. While current evidence supports its safety and efficacy, further research is needed to establish long-term outcomes and optimal use in pediatric populations. With appropriate monitoring, oral minoxidil represents a promising therapeutic option in the management of hair loss disorders.
